Explore Our Science
We have a breadth of clinical programs within our portfolio across Myeloproliferative Neoplasms (MPNs) and Graft-Versus-Host Disease (GVHD), General Hematology/Oncology, Dermatology and other Inflammation & Autoimmunity (IAI), and Partnered Programs.
Our Portfolio
Molecular Targets
Clinical Compounds
Approved Products
MPNs and GVHD
Jakafi® (ruxolitinib)1
Myelofibrosis2, polycythemia vera2, GVHD2
status for mobile
NiktimvoTM (axatilimab-csfr)3
3L+ chronic GVHD2
status for mobile
ruxolitinib XR (QD)
Bioequivalence and stability testing
status for mobile
axatilimab3
1L chronic GVHD
status for mobile
axatilimab3
1L chronic GVHD | + ruxolitinib
status for mobile
zilurgisertib
Myelofibrosis-associated anemia
| ± ruxolitinib
status for mobile
INCB057643
Myelofibrosis | ± ruxolitinib
status for mobile
INCA033989
Myelofibrosis or ET with CALR mutation | ± ruxolitinib
status for mobile
INCB160058
JAK2V617F-mutated myelofibrosis
status for mobile
General Hematology/Oncology
Pemazyre® (pemigatinib)
2L+ cholangiocarcinoma4, MLNs with FGFR1 rearrangement2,5
status for mobile
Monjuvi® (tafasitamab-cxix)
Minjuvi® (tafasitamab)
r/r DLBCL2,6,7
status for mobile
Iclusig® (ponatinib)8
Chronic myeloid leukemia7,
Ph+ ALL7
status for mobile
Zynyz® (retifanlimab-dlwr)9
Zynyz® (retifanlimab)9
Merkel cell carcinoma2,7
status for mobile
tafasitamab
r/r follicular lymphoma, r/r MZL,
1L DLBCL
status for mobile
retifanlimab9
Squamous cell carcinoma of the anal canal, NSCLC
status for mobile
retifanlimab9
MSI-H endometrial cancer
status for mobile
INCB123667
Solid tumors
status for mobile
INCA3389010
Solid tumors
status for mobile
INCB161734
KRASG12D-mutated solid tumors
status for mobile
Dermatology and Other IAI
Opzelura® (ruxolitinib) cream
AD2,6, vitiligo2,6,7
status for mobile
ruxolitinib cream
Pediatric AD, prurigo nodularis, pediatric vitiligo
status for mobile
ruxolitinib cream
Hidradenitis suppurativa, lichen sclerosus
status for mobile
povorcitinib
Hidradenitis suppurativa, vitiligo, prurigo nodularis
status for mobile
povorcitinib
CSU, asthma
status for mobile
INCB000262 (EP262)
CSU, chronic inducible urticaria, AD
status for mobile
INCB000547 (EP547)
Cholestatic pruritus
status for mobile
zilurgisertib
Fibrodysplasia ossificans progressiva
status for mobile
Partnered Programs
Olumiant® (baricitinib)11
Rheumatoid arthritis12, COVID-1912, AD5,7, alopecia areata12
status for mobile
Tabrecta® (capmatinib)13
NSCLC with METex1412
status for mobile
axatilimab3
Idiopathic pulmonary fibrosis14
status for mobile
Updated as of October 29, 2024
Please refer to local prescribing information for more information, including full safety information, on Incyte’s marketed medicines, or on medicines marketed by Incyte’s collaboration partners.
1. Marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis outside the U.S. 2. Approved in the U.S. 3. In collaboration with Syndax 4. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 5. Approved in Japan 6. Approved in Canada 7. Approved in Europe 8. European rights to Iclusig licensed from Takeda 9. Licensed from MacroGenics 10. Development in collaboration with Merus 11. Worldwide rights to baricitinib licensed to Lilly 12. Approved in multiple territories globally 13. Worldwide rights to capmatinib licensed to Novartis 14. IPF study currently led and funded by Syndax
1L, first-line; 2L+, second-line or later; 3L+, third-line or later; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; CSU, chronic spontaneous urticaria; DLBCL, diffuse large B-cell lymphoma; ET, essential thrombocythemia; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IAI, inflammation and autoimmunity; IPF, idiopathic pulmonary fibrosis; mAb, monoclonal antibody; MLNs, myeloid/lymphoid neoplasms; MPNs, myeloproliferative neoplasms; MSI-H, microsatellite instability-high; mut, mutant; MZL, marginal zone lymphoma; NSCLC, non-small cell lung cancer; Ph+, Philadelphia chromosome-positive; QD, once daily; r/r, relapsed or refractory; XR, extended release.
Clinical Trials
At Incyte, we believe in the power of research to advance scientific innovation and improve patient health. Thanks to the ongoing dedication of the people who participate in our clinical trials, we strive to develop medicines that have the potential to make a meaningful difference in the treatment of disease.
Our Incyte Clinical Trials website provides information for patients and healthcare professionals, including the basics of how clinical trials work and details about clinical studies that Incyte is currently sponsoring across a number of therapeutic areas, including Oncology and Inflammation & Autoimmunity.
Clinical Trial Information for U.S. Patients
Clinical Trial Information for Healthcare Professionals
Are you a physician, researcher or institution representative interested in conducting external research?
Incyte supports significant independent research aimed at enhancing disease understanding and advancing the study of our products by generating health outcomes data and real-world evidence.
Proposals submitted to Incyte are reviewed by Incyte's scientific and medical committees, with approval based on scientific merit, patient-safety considerations, unmet medical needs, study design, availability of resources and feasibility of study conduct. If you’re interested in submitting a research proposal, please visit our online research portal.
For questions concerning Investigator Initiated Research conducted outside of the U.S., please contact Incyte at global_iir@incyte.com.
For questions concerning Investigator Initiated Research conducted in the U.S., please contact Incyte at us_iir@incyte.com.